We report an asymmetric synthesis of (-)-Levetiracetam (1) in six steps starting from versatile new chiral N-sul�nimine (3). e key step, stereoselective 1,2-addition of ethylmagnesium bromide (EtMgBr) to chiral N-sul�nimine derived from (R)-glyceraldehyde acetonide and (S)-t-BSA, gave the corresponding sulfonamide (2) in high diastereoselectivity. Simultaneous deprotection and deacetylation followed by NaIO 4 cleavage and reduction gave -amino alcohol (6). Subsequent reactions yielded the targeted compound levetiracetam (1).
Introduction
Epilepsy is a chronic neurological disorder that consists of repeated occurrences of spontaneous seizures. Levetiracetam, (S)--ethyl-2-oxopyrrolidine acetamide (1), has been approved as an add-on therapy for the treatment of refractory epilepsy [1] . e (S)-enantiomer of etiracetam (levetiracetam) has shown outstanding pharmacokinetic and pharmacological activity that has led to the rapid approval of this antiepileptic drug by the FDA (Figure 1 ). Levetiracetam offers several advantages over traditional therapy, including twice daily dosing, which includes a wide margin of safety with no requirements for serum drug concentration monitoring and no interactions with other anticonvulsants besides having less adverse effects than traditional treatments [2] [3] [4] .
e literature methods for the synthesis of levetiracetam typically involve chiral pool approaches starting from enantiopure -amino acids, resolution of etiracetam or advanced racemic intermediates [5] [6] [7] [8] , asymmetric hydrogenation over Rh(I) or Ru(II) complexes [9, 10] , and deracemization of 2-bromobutyric acid using N-phenyl pantolactam as a chiral auxiliary [11] . As a part of our research program, aimed at developing stereo controlled syntheses of bioactive molecules [12] [13] [14] [15] [16] [17] , we report a new and enantioselective synthesis of levetiracetam (1) using versatile N-sul�nimine as starting material and (S)-t-BSA [18] as a chiral auxiliary. It demonstrates the versatility and important extended application of N-sul�nimine in the preparation of variety of biological active and pharmaceutical important molecules [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .
e �eld of asymmetric organocatalysis is rapidly developing and has attracted the attention of an increasing number of research groups around the world. In particular, organo catalytic asymmetric synthesis has provided several new methods for obtaining chiral compounds. In this connection, t-BSA is abundant, inexpensive, and readily available in both enantiomeric forms and has emerged as arguably the most practical and versatile organo catalyst (S)-t-BSA has also been found to be an excellent asymmetric catalyst for -amino alcohol functionalities (Figure 2) .
We envisage the new chiral N-sul�nimine amongst the best starting material for functionalized amino alcohols, amino acids [30] [31] [32] [33] [34] [35] [36] , and amino diols. Hence, utilizing this versatile chiral building block, we successfully synthesized (S)-2-amino-1-butanol (6), a precursor for the asymmetric synthesis of 2-pyrrolidone derivatives like levetiracetam. us, we have successfully achieved the enantioselective synthesis of levetiracetam by employing (S)-t-BSA as a chiral catalyst and N-sul�nimine (3) as versatile chiral building block.
Experimental Section
All reagents and solvents employed were of commercial grade and were used as such, unless otherwise speci�ed. Reaction �asks were oven-dried at 200 ∘ C, �ame-dried, and �ushed with dry nitrogen prior to use. All moisture and airsensitive reactions were carried out under an atmosphere of dry nitrogen. TLC was performed on Kieselgel 60 F254 silica-coated aluminium plates (Merck) and visualized by UV light ( = 254 nm) or by spraying with a solution of KMnO 4 . Organic extracts were dried over anhydrous Na 2 SO 4 . Flash chromatography was performed using Kieselgel 60 brand silica gel (230-400 mesh). e melting points were determined in an open capillary tube using a Büchi B-540 melting point instrument and were uncorrected. e IR spectra were obtained on a Nicolet 380 FT-IR instrument (neat for liquids and as KBr pellets for solids). NMR spectra were recorded with a Varian 300 MHz Mercury Plus Spectrometer at 300 MHz ( 1 H) and at 75 MHz ( 13 C). Chemical shis were given in ppm relative to trimethylsilane (TMS). Mass spectra were recorded on Waters quattro premier XE triple quadrupole spectrometer using either electron spray ionisation (ESI) or atmospheric pressure chemical ionization (APCI) technique. 
Preparation of (S,E)-N-(((S
)
Preparation of (S)-N-((S)-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)(Ethyl) �ethyl)-2-methyl propane-2-�ul�namide (2).
A solution of Sul�nimine 3 (10.0 g, 0.428 mol) in diethyl ether (50.0 mL) was cooled to −78 ∘ C. In another �ask, ethylmagnesium bromide (30.0 mL, 0.85 mol, 3.0 M in ether) was added to a solution of TMEDA (10.1 g, 0.87 mol) in diethyl ether (2.0 M). is mixture was then transferred to sul�nimine solution. Aer completion of reaction was added NH 4 Cl (50.0 mL) extracted with EtOAc (3 × 100 mL). e organic solution was dried with (Na 2 SO 4 ) distilled under vacuo to give compound 2 as oil. e residue was subjected to silica gel column chromatography (eluent: AcOEt/hexane 1 : 2) give pure 2 (9.0 g, 80% 
Preparation of (2S,3S)-3-Aminopentane-1,2-diol Hydrochloride (5).
To a solution of protected chiral amine 2 (5.0 g, 0.018 mol) in methanol (50 mL) was added dropwise a solution of MeOH-HCl (10%) (34.0 mL, 0.094 mol). e solution was stirred for 2 h at room temperature and was then concentrated in vacuo. e amine hydrochloride was obtained as a white solid aer precipitation from ether and was used without further puri�cation of compound 5 (2. 
Preparation of (S)-2-Aminobutan-1-ol (6).
Prepare solution of protected chiral amine diol 5 (2.0 g, 0.128 mol) by drop wise addition in water (10 mL). A few drops of acetone were needed for complete solubilization. NaIO 4 (2.73 g, 0.128 mol) was added portionwise at 0 ∘ C. Aer 60 min NaBH 4 (0.6 g, 0.153 mol) was added slowly. e solution was stirred for 3 h at room temperature, then acidi�ed with dilute hydrochloric acid and extracted with ethyl acetate (3 × 30 mL). e �ltrate [Lit., [38] 
Preparation of 1-((S
Preparation of (S)-2-(2-Oxopyrrolidin-1-yl)butanoic Acid (8).
Potassium hydroxide (1.0 g, 0.017 mol) was dissolved into water (18.0 mL). Tetra-n-butyl ammonium bromide (0.2 g, 0.0062 mol) and (S)-7 (1.0 g, 0.0063 mol) in methylene chloride (10 mL) were charged in 30 min charged potassium permanganate (1.5 g, 0.094 mol), aer completion of reaction �ltered through a celite bed and washed with water (10.0 mL). e aqueous layer pH was adjusted to 3 using hydrochloric acid (2 mL), added sodium phosphate (2.5 g, 0.0152 mol) and toluene (25.0 mL). e reaction mixture was extracted with dichloromethane (5 × 25 mL). e organic solution was dried with (Na 2 SO 4 ) distilled under vacuum to give compound 8 as oil. To the residue toluene (10 mL) was added and stirred at 0 ∘ C for about 30 min. e solid was �ltered and washed with toluene (5 mL) to afford the pure compound 8 (0.83 g, 76%); Mp: 124-125 ∘ C [Lit., [11] 
Preparation of (S)-2-(2-Oxopyrrolidin-1-yl) Butanamide: (-)-Levetiracetam (1).
To a cold (0 ∘ C) solution of acid (S)-8 (5.0 g, 0.292 mol) and Et 3 N (4.3 mL, 0.307 mol) in anhydrous THF (20 mL) was added ethyl chloroformate (2.9 mL, 0.304 mol) and the mixture stirred at 0 ∘ C for 30 min. Ammonium hydroxide (25% w/v aqueous solution, 19.0 mL, 136.0 mol) was added, and the reaction mixture was le to stir at room temperature for 12 h. Aer the addition of K 2 CO 3 (4.14 g, 30.0 mol), the mixture was �ltered and the volatile materials (solvent and Et 3 N) distilled off in vacuo. e solid residue was extracted with CH 2 Cl 2 (3 × 50 mL) and the combined organic extracts dried over Na 2 SO 4 and concentrated in vacuo recrystallization from acetone (100 mL) give 1 (3.3 g, 65%) a white solid, chiral HPLC 
Results and Discussion
In connection with a current research program, we required an efficient route for the preparation of chiral amino alcohols followed by synthesis of biologically active 2-pyrrolidone derivatives ((-)-levetiracetam, brivaracetam…). Despite the potential synthetic utility of the multiple functionalities present in N-sul�nimine (3), we have successfully synthesized taxol side chain precursor (4S,5S)-2-oxo-4-phenyloxazolidine-5-carboxylic acid [37] and (+)-cytoxazone. Herein, we report an asymmetric synthesis of (1) via stereoselective 1,2-addition of ethylmagnesium bromide (EtMgBr) to N-sul�nimine. In this context, (R)-glyceraldehyde acetonide is regarded as a common starting material which has previously been synthesized using a new route in our laboratory in four steps and in 31% overall yield starting from commercially available (R)-epichlorohydrin. (R)-Glyceraldehyde acetonide was earlier elaborated in getting (S,E)-N-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl) methylene)-2-methyl propane-2-sul�namide 3 by the CuSO 4 catalyzed reaction of (R)-glyceraldehyde acetonide with (S)-t-butylsul�namide ((S)-t-BSA) in dichloromethane at room temperature in 98.94% de (Scheme 1) [37] . Among the various methods, nucleophilic 1,2-addition of aryl or alkyl carbanion to an imine double bond is a versatile and popular method for the preparation of functionalised amines. However, in this strategy both yield and stereoselectivity are predominantly in�uenced by electrostatic and steric factors of both substrates, that is, imine and the nucleophile. Incorporation of a stereo-directing motif such as chiral sul�nimines is evident for its potential to synthesize chiral amines in stereoselective fashion.
It is apparent that 1,2-addition of EtMgBr to chiral sul�nimine 3 proceeds via transition state (Figure 3 ). Stereoselectivity resulting from the addition of organometallic reagents to the C-N double bond of sul�nimines can generally be predicted by assuming chelated, chairlike transition states resulting from coordination of the metal ion with the sul�nyl oxygen. e chiral -hydroxy-N-sul�nimines have recently received much attention as important precursors and intermediates for the preparation of a wide variety of natural products and drugs [39] . Furthermore, they can be easily converted into chiral -amino alcohols and 2-oxazolidinones. erefore, development of methodologies for the stereoselective synthesis of chiral -Amino alcohols followed by 2-pyrrolidone ring formation to levetiracetam (1) is of considerable interest [40] .
Only in diethyl ether as a solvent reaction completion within 5-6 hr was observed and alternate solvents such as THF, toluene, and CH 2 Cl 2 did not enhance the yields and selectivity (Table 1 . Entries 2, 3, and 4). e addition of the Grignard reagent to the imines 3 in THF at −78 ∘ C gave good selectivity and observed single diastereomer in reaction monitored by TLC. Same reaction but in different solvents was carried out at the same temperature. However, incomplete reactions were observed. Rising to RT, complete conversion was observed but with low selectivity, and mixture of diastereomeric was observed by TLC. Higher temperatures lead, reaction completion. Deprotection of the tbutylsul�nyl group and 1,3-dimethyl acetal in compound 2 was performed in single step in acidic media (MeOH⋅HCl) to give the corresponding -amino diol 5. Oxidation followed by reduction of amino diol in 5 using NaIO 4 /NaBH 4 gave the corresponding -amino alcohol [41] 6. e compound 6 on reaction with 4-chlorobutyryl chloride [42] gave 2-pyrrolidone alcohol 7. e oxidation of 7 with KMnO 4 gave 8, and resultant amidation yielded (Scheme 2) the targeted (-)-levetiracetam 1. e spectral data for which were found to be in good agreement with reported values in the literature [38] .
In conclusion, an efficient method has been developed for the preparation of levetiracetam 1 starting from chiral N-sul�nimine. e key step comprises a stereoselective 1,2-addition of ethylmagnesium bromide (EtMgBr) to chiral Nsul�nimine 3. e synthetic strategy detailed herein is equally applicable to the synthesis of the brivaracetam. Further application of this strategy to a variety of related natural products is currently underway in our laboratories.
